Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ORMP | ORAMED PHARMACEUTICALS INC. | 2025-10-30 15:37:59 | 2.42 | 0.02 | 0.83 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORMP | 0001176309 | ORAMED PHARMACEUTICALS INC. | US68403P2039 | 5299006K52ZIIGQJ6R84 | 980376008 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR | NEW YORK | NY | 10036 | UNITED STATES | US | 646-844-1164 | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036 | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036 | Integrated Security Technologies, Inc. | Biotech | 2006 | Nadav Kidron | — | http://oramed.com | 131,190,607 | 40,845,087 | 41,003,600 | Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange. | 2025-10-30 16:24:18 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 131,190,607 | 665,085 | 0.5095 | 40,850,455 | 331,295 | 0.8176 |
| 2023 | 130,525,522 | -39,068,827 | -23.0366 | 40,519,160 | 735,347 | 1.8484 |
| 2022 | 169,594,349 | -58,175,429 | -25.5413 | 39,783,813 | 1,697,793 | 4.4578 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Dr. Miriam Kidron | Chief Scientific Officer, Director | 2024 | 408,104 | 155,291 | — | — | 19,607 | 1,534,547 |
| Nadav Kidron | Chief Executive Officer, Chairman, President | 2024 | 540,145 | 270,767 | — | — | 62,017 | 2,097,689 |
| Nadav Kidron | Chief Executive Officer, Chairman, President | 2023 | 462,988 | 242,576 | — | — | 48,738 | 1,659,222 |
| Dr. Miriam Kidron | Chief Scientific Officer, Director | 2023 | 347,405 | 139,123 | — | — | 17,423 | 1,109,431 |
| David Silberman | Chief Financial Officer | 2023 | 156,070 | 62,027 | — | — | 41,434 | 536,711 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | 1,340,000 | 2,703,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 6,324,000 | 8,971,000 | 27,639,000 |
| General And Administrative Expenses | 6,457,000 | 8,425,000 | 13,811,000 |
| Operating Expenses | — | — | — |
| Operating Income | -12,781,000 | -15,769,000 | -40,598,000 |
| Net Income | -19,103,000 | 5,525,000 | -37,764,000 |
| Earnings Per Share Basic | -0.48 | 0.14 | 0.94 |
| Earnings Per Share Diluted | -0.48 | 0.14 | 0.94 |
| Weighted Average Shares Outstanding Basic | 40,828,380 | 40,315,068 | 38,997,649 |
| Weighted Average Shares Outstanding Diluted | 40,828,380 | 40,566,901 | 38,997,649 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 54,420,000 | 9,055,000 | 40,464,000 |
| Marketable Securities Current | 3,441,000 | — | 3,743,000 |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 143,221,000 | 162,584,000 | 157,109,000 |
| Marketable Securities Non Current | — | 1,807,000 | 2,700,000 |
| Property Plant And Equipment | 698,000 | 873,000 | 815,000 |
| Other Assets Non Current | 32,000 | — | — |
| Total Assets Non Current | 12,057,000 | 57,967,000 | 4,533,000 |
| Total Assets | 155,278,000 | 220,551,000 | 161,642,000 |
| Accounts Payable | 789,000 | 551,000 | 2,175,000 |
| Deferred Revenue | — | — | 2,000,000 |
| Short Term Debt | — | 51,013,000 | — |
| Other Liabilities Current | 59,000 | 59,000 | 133,000 |
| Total Liabilities Current | 5,685,000 | 53,214,000 | 5,746,000 |
| Long Term Debt | — | — | 25,000 |
| Other Liabilities Non Current | 60,000 | — | — |
| Total Liabilities Non Current | 4,246,000 | 4,444,000 | 4,740,000 |
| Total Liabilities | 9,931,000 | 57,658,000 | 10,486,000 |
| Common Stock | 480,000 | 485,000 | 476,000 |
| Retained Earnings | -176,616,000 | -157,556,000 | -163,081,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 146,265,000 | 163,821,000 | 151,812,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 193,000 | 196,000 | 58,000 |
| Share Based Compensation Expense | 4,053,000 | 4,212,000 | 11,509,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 3,525,000 | -2,225,000 | — |
| Change In Other Liabilities | — | — | 93,000 |
| Cash From Operating Activities | -8,412,000 | -10,295,000 | -27,918,000 |
| Purchases Of Marketable Securities | 1,307,000 | 91,369,000 | 151,700,000 |
| Sales Of Marketable Securities | 64,500,000 | 109,760,000 | — |
| Acquisition Of Property Plant And Equipment | 18,000 | 254,000 | 496,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 105,817,000 | -73,038,000 | 30,211,000 |
| Tax Withholding For Share Based Compensation | 2,000 | — | 783,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | 2,428,000 | 10,617,000 |
| Repurchase Of Common Stock | 2,484,000 | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -52,036,000 | 51,978,000 | 10,779,000 |
| Change In Cash | 45,365,000 | -31,409,000 | 13,008,000 |
| Cash At End Of Period | 54,420,000 | 9,055,000 | 40,464,000 |
| Income Taxes Paid | — | — | 100,000 |
| Interest Paid | 2,316,000 | 574,000 | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.48 | 0.14 | 0.94 |
| Price To Earnings Ratio | -5.0417 | 16.5 | 12.7979 |
| Earnings Growth Rate | -442.8571 | -85.1064 | — |
| Price Earnings To Growth Ratio | 0.0114 | -0.1939 | — |
| Book Value Per Share | 3.56 | 4.0405 | 3.876 |
| Price To Book Ratio | 0.6798 | 0.5717 | 3.1037 |
| Ebitda | -16,323,000 | 7,758,000 | -37,606,000 |
| Enterprise Value | — | — | 428,702,717.47 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | 0.0002 |
| Capital Expenditures | 18,000 | 254,000 | 476,000 |
| Free Cash Flow | -8,430,000 | -10,549,000 | -28,394,000 |
| Return On Equity | -0.1306 | 0.0337 | -0.2488 |
| One Year Beta | 0.8615 | 0.511 | 1.8824 |
| Three Year Beta | 1.4232 | 1.5531 | 1.0167 |
| Five Year Beta | 0.9591 | 0.9233 | 0.9262 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Shapiro Benjamin | Director | 2025-06-05 | 30,000 | A | 85,070 |
| Shapiro Benjamin | Director | 2025-06-05 | 4,650 | A | 89,720 |
| Sank Leonard | Director | 2025-06-05 | 30,000 | A | 128,021 |
| Sank Leonard | Director | 2025-06-05 | 6,510 | A | 134,531 |
| Reznick Yehuda | Director | 2025-06-05 | 30,000 | A | 60,560 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Brad Knott | 2025-02-25 | NC13 | Sale | 2025-01-10 | — | $15,001 - $50,000 |
| Andrew Garbarino | 2022-01-14 | NY02 | Sale | 2022-01-14 | — | $1,001 - $15,000 |
| Andrew Garbarino | 2021-11-03 | NY02 | Sale (Partial) | 2021-10-01 | — | $1,001 - $15,000 |
| Andrew Garbarino | 2021-05-24 | NY02 | Purchase | 2021-04-23 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2025-09-30 | 46,622 | 18,799 | 2.48 |
| Glass Jacobson Investment Advisors llc | 2025-09-30 | 27,826 | 10,540 | 2.64 |
| Sage Capital Management, LLC | 2025-09-30 | 44,220 | 16,750 | 2.64 |
| McIlrath & Eck, LLC | 2025-09-30 | 2,640 | 1,000 | 2.64 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 9,712 | 4,317 | 2.2497 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | Avantis U.S. Small Cap Equity ETF | AVSC | 15,439 | 33,965.8 | 0.0018 |
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | Avantis U.S. Equity ETF | AVUS | 4,152 | 9,134.4 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 24,282 | 53,420.4 | 0.0003 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 2025-07-31 | U.S. Targeted Value Portfolio - Institutional Class | DFFVX | 13,879 | 29,839.85 | 0.0002 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 2025-07-31 | U.S. CORE EQUITY 1 PORTFOLIO - INSTITUTIONAL CLASS | DFEOX | 3,131 | 6,731.65 | 0.0 |